Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trialsNicola A. Hanania, John G. Matthews, Petr Kopecký et al.|The Lancet Respiratory Medicine|2016Cited by 465
Future Directions in Idiopathic Pulmonary Fibrosis Research. An NHLBI Workshop ReportTimothy S. Blackwell, Jerry P. Eu, Andrew M. Tager et al.|American Journal of Respiratory and Critical Care Medicine|2013Cited by 247